Pharmacotherapy in patients undergoing CABG
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization (Please do not edit). Pharmacotherapy in patients undergoing CABG
Insulin Infusion and Other Measures to Reduce Sternal Wound Infection in Patients Undergoing CABG
| Class I |
| "1. In patients undergoing CABG, an intraoperative continuous insulin infusion should be initiated to maintain serum glucose level <180 mg/dL to reduce sternal wound infection(Level of Evidence: B-R) " |
| "2. In patients undergoing CABG, the use of continuous intravenous insulin to achieve and maintain an early postoperative blood glucose concentration of <180 mg/dL while avoiding hypoglycemia is indicated to reduce the incidence of adverse events, including deep sternal wound infection. (Level of Evidence: B-R) " |
| "3. In patients undergoing CABG, a comprehensive approach to reducing sternal wound infections is recommended(Level of Evidence: B-NR) " |
References
- ↑ "Correction to: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (11): e771. 2022. doi:10.1161/CIR.0000000000001061. PMID 35286170 Check
|pmid=value (help).